Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment (Q28082086)

language of work or name

1 reference

May 2015

1 reference

American Journal of Hematology

published in

1 reference

volume

90

1 reference

issue

5

1 reference

page(s)

446-60

1 reference

cites work

Cancer statistics, 2007

1 reference

Sex differences in incidence and outcome of chronic lymphocytic leukemia patients

21 January 2018

1 reference

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

21 January 2018

1 reference

Disease burden of chronic lymphocytic leukaemia within the European Union

21 January 2018

1 reference

Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia

21 January 2018

1 reference

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

21 January 2018

1 reference

Chronic lymphocytic leukemia

21 January 2018

1 reference

The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia

21 January 2018

1 reference

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

21 January 2018

1 reference

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia

21 January 2018

1 reference

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

21 January 2018

1 reference

The DNA-damage response in human biology and disease

21 January 2018

1 reference

Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia

21 January 2018

1 reference

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

21 January 2018

1 reference

Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor

21 January 2018

1 reference

State-of-the-art treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies

21 January 2018

1 reference

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

Diagnostic criteria for monoclonal B-cell lymphocytosis

21 January 2018

1 reference

Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia

21 January 2018

1 reference

Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b).

21 January 2018

1 reference

Levels of expression of CD19 and CD20 in chronic B cell leukaemias

21 January 2018

1 reference

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

21 January 2018

1 reference

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

21 January 2018

1 reference

Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

21 January 2018

1 reference

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Validation of a new prognostic index for patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?

21 January 2018

1 reference

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

21 January 2018

1 reference

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101

21 January 2018

1 reference

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

Aminos�ureantagonisten. III. ?-[Bis-(?-chlor�thyl)-amino-benzimidazolyl-(2)]-propion- bzw. -butters�uren als potentielle Cytostatika

21 January 2018

1 reference

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

21 January 2018

1 reference

Novel CD20 monoclonal antibodies for lymphoma therapy

21 January 2018

1 reference

Anti-CD20 antibody therapy for B-cell lymphomas

21 January 2018

1 reference

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

21 January 2018

1 reference

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

21 January 2018

1 reference

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

21 January 2018

1 reference

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

21 January 2018

1 reference

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

21 January 2018

1 reference

B-cell receptor signaling in chronic lymphocytic leukemia.

21 January 2018

1 reference

B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase

21 January 2018

1 reference

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

PI3K in lymphocyte development, differentiation and activation

21 January 2018

1 reference

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

21 January 2018

1 reference

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

21 January 2018

1 reference

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

21 January 2018

1 reference

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes

21 January 2018

1 reference

Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals

21 January 2018

1 reference

Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia

21 January 2018

1 reference

Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells

21 January 2018

1 reference

Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia

21 January 2018

1 reference

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

BCL-2 family: regulators of cell death

21 January 2018

1 reference

Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation

21 January 2018

1 reference

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance

21 January 2018

1 reference

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

21 January 2018

1 reference

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

21 January 2018

1 reference

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

21 January 2018

1 reference

Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia

21 January 2018

1 reference

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

21 January 2018

1 reference

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.

21 January 2018

1 reference

Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia

21 January 2018

1 reference

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

21 January 2018

1 reference

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

21 January 2018

1 reference

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

21 January 2018

1 reference

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

21 January 2018

1 reference

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

21 January 2018

1 reference

A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

21 January 2018

1 reference

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

21 January 2018

1 reference

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

21 January 2018

1 reference

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

21 January 2018

1 reference

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

21 January 2018

1 reference

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages.

21 January 2018

1 reference

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity

21 January 2018

1 reference

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

21 January 2018

1 reference

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

21 January 2018

1 reference

Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

21 January 2018

1 reference

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

21 January 2018

1 reference

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23979

1 reference

Consolidated OpenCitations Corpus – April 2017

2062734

2062734

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference